Actively Recruiting
Evaluating Bedaquiline Compared to Standard Regimens to Prevent Tuberculosis in People Living With HIV and High-Risk Contacts
Led by Johns Hopkins University · Updated on 2026-10-20
2530
Participants Needed
8
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of bedaquiline compared to standard treatments to prevent tuberculosis disease in people living with HIV and close contacts of adults with drug-susceptible or rifampin-resistant tuberculosis. This Phase IIIII open-label trial aims to show that 4 weeks of bedaquiline is not less effective than current WHO-recommended regimens for preventing tuberculosis in these high-risk groups. Participants are assigned to one of three treatment groups 4 weeks of daily bedaquiline, 3 months of weekly isoniazid and rifapentine, or 6 months of daily levofloxacin. The study includes groups at high risk, such as children, adolescents, adults, pregnant people, and people living with HIV, with treatments adjusted by weight or age. Treatment durations vary by regimen, and those with rifampin-resistant tuberculosis receive levofloxacin. During the study, participants undergo safety and treatment completion assessments up to 18 or 36 weeks depending on the group. Researchers monitor for adverse events, treatment adherence, and incidence of tuberculosis disease for up to 72 weeks after treatment starts. Laboratory tests, chest x-rays, and pregnancy tests are conducted before enrollment, and safety is closely followed throughout the study period lasting over one year from treatment initiation.
CONDITIONS
Brief Title
Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB
Research Team
B
Bonnie S. King, MHS
K
Kate Boehner, RN, MSN
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here